SMCI: Revenue Surge and Cheap Valuation Flip Thesis to Buy

What happened

SMCI shares have fallen nearly 40% since early October despite reporting Q1 FY2027 revenue of $19.9 billion, up 298% year-over-year, and raising FY2027 revenue guidance to $72-$82 billion. The decline left the stock well below the $33 attractive entry level identified in our prior report. Management noted cash conversion improved from 149 to 97 days, although operating cash flow remained negative at $434 million. The quarter's strong revenue and guidance suggest backlog conversion is accelerating, but the market remains concerned about cash generation and thin margins. With the stock now cheaper and fundamentals improving, the risk-reward has shifted favorably.

Implication

The stock's 40% drop appears overdone relative to the revenue beat and raised guidance, bringing it below our attractive entry price. However, investors should demand confirmation that the negative operating cash flow is a temporary working-capital issue rather than a structural problem, and that gross margin can sustain above 13%. The improvement in cash conversion to 97 days is a positive sign, but inventory levels must continue to decline. Export-control risk remains a live issue. We would initiate or add to positions, while monitoring the next quarter for cash flow inflection and margin durability.

Thesis delta

The thesis shifts from WAIT to BUY. Q1 FY2027 revenue of $19.9 billion exceeds the $14.5-$15.5 billion threshold we set, and FY2027 guidance raised to $72-$82 billion validates backlog conversion. With shares down 40% since October, the stock now trades below our attractive entry of $33, improving risk-reward.